Slenyto is approved in Canada

We are pleased to announce that Health Canada has granted marketing authorization for Slenyto®- Extended-Release Melatonin Formulation – as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome. This approval marks a significant advancement in pediatric sleep medicine for Canadian patients, offering a clinically proven, well-tolerated, and child-friendly remedy for children with ASD affected by chronic sleep disturbances and their families. Read our press release: https://rb.gy/vbpjcz

The release as fetched from its publisher. neurim.com ↗